BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 637 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 637 shares of the company's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $23.70, for a total value of $15,096.90. Following the completion of the transaction, the executive vice president now owns 353,118 shares of the company's stock, valued at $8,368,896.60. The trade was a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

BioLife Solutions Trading Down 5.5%

Shares of BioLife Solutions stock traded down $1.27 on Friday, hitting $22.03. 820,307 shares of the company's stock traded hands, compared to its average volume of 406,431. The firm's 50-day moving average price is $22.72 and its two-hundred day moving average price is $24.95. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a market capitalization of $1.05 billion, a PE ratio of -20.78 and a beta of 1.82. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $23.94 million during the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of BioLife Solutions

Several hedge funds have recently added to or reduced their stakes in BLFS. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the fourth quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions during the 4th quarter worth approximately $31,000. State of Wyoming raised its holdings in BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after buying an additional 1,490 shares during the period. US Bancorp DE boosted its holdings in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after buying an additional 1,528 shares during the period. Finally, 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after acquiring an additional 675 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.